The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Esophageal Cancer Action Network (ECAN); Esophageal Cancer Action Network (ECAN); Esophageal Cancer Action Network (ECAN); Esophageal Cancer Action Network (ECAN); National Comprehensive Cancer Network; National Comprehensive Cancer Network; National Comprehensive Cancer Network; National Comprehensive Cancer Network
Research Funding - National Comprehensive Cancer Network (Inst); National Comprehensive Cancer Network (Inst); National Comprehensive Cancer Network (Inst); National Comprehensive Cancer Network (Inst); North American Neuroendocrine Tumor Society (Inst); North American Neuroendocrine Tumor Society (Inst); North American Neuroendocrine Tumor Society (Inst); North American Neuroendocrine Tumor Society (Inst)
Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in advanced hepatocellular cancer (HCC).
 
Rohit Gosain
No Relationships to Disclose
 
Sarbajit Mukherjee
No Relationships to Disclose
 
Sunyoung S. Lee
No Relationships to Disclose
 
Austin Miller
No Relationships to Disclose
 
Hans Minderman
No Relationships to Disclose
 
Orla Maguire
No Relationships to Disclose
 
Junko Matsuzaki
No Relationships to Disclose
 
Danielle Casucci
No Relationships to Disclose
 
Devalingam Mahalingam
Honoraria - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech; Genentech; Genentech; Genentech
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech; Genentech; Genentech; Genentech
Research Funding - Merck; Merck; Merck; Merck
 
Renuka V. Iyer
Honoraria - Ipsen; Ipsen; Ipsen; Ipsen
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; Lexicon; Lexicon; Lexicon; Lexicon; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Novartis; Novartis; Novartis; Novartis
Research Funding - Cleveland BioLabs (Inst); Cleveland BioLabs (Inst); Cleveland BioLabs (Inst); Cleveland BioLabs (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)